BIG 2-13 / CL2-80881-001 (FINESSE)ClinicalTrials.gov Identifier:
Breast International Group
Frontier Science Scotland
To evaluate the objective response rate (ORR) of single agent lucitanib in metastatic breast cancer patients with FGFR1-amplified, FGFR1-non amplified with 11q amplification, or FGFR1-non amplified without 11q amplification.
This study is the first international trial in the metastatic setting to be carried out by the BrEAST Data Centre. This represents a new milestone for our organization. This trial is evaluating a FGFR inhibitor and determining if the benefit is restricted or not in patients according to FGFR amplification.
Recruitment started in December 2013 and the study is expected to complete in Q2/3 2016. Around 20-25 sites are participating in this trial.